AbbVie Inc (ABBV)vsAddus HomeCare Corporation (ADUS)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
ADUS
Addus HomeCare Corporation
$96.89
-0.07%
HEALTHCARE · Cap: $1.81B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4199% more annual revenue ($61.16B vs $1.42B). ABBV leads profitability with a 6.9% profit margin vs 6.7%. ABBV appears more attractively valued with a PEG of 0.48. ADUS earns a higher WallStSmart Score of 70/100 (B).
ABBV
Buy63
out of 100
Grade: C+
ADUS
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+25.9%
Fair Value
$152.11
Current Price
$96.89
$55.22 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Earnings expanding 52.1% YoY
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 25.6% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
6.7% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ADUS
The strongest argument for ADUS centers on EPS Growth, Altman Z-Score, PEG Ratio. Revenue growth of 25.6% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ADUS
The primary concerns for ADUS are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while ADUS is a growth play — different risk/reward profiles.
ADUS carries more volatility with a beta of 0.96 — expect wider price swings.
ADUS is growing revenue faster at 25.6% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ADUS scores higher overall (70/100 vs 63/100) and 25.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Addus HomeCare Corporation
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Addus HomeCare Corporation, provides personal care services to the elderly, the chronically ill, the disabled, and people who are at risk of hospitalization or institutionalization in the United States. The company is headquartered in Frisco, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?